At Avalo (ahh-vah'-low), we are 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1 pathway, which is a central driver of the inflammatory process.
We share a commitment to teamwork, passion for science, and dedication to patients suffering from acute and chronic inflammatory disorders. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.
Position Summary:
Avalo is a publicly traded, clinical-stage biotechnology company advancing abdakibart into Phase 3. As the company moves toward late-stage development and potential commercialization, its technology foundation must scale to be secure, validated, inspection-ready, and built to support a growing, distributed workforce.
The Vice President, Enterprise Technology will build and lead the technology platform that carries the company from Phase 2 into Phase 3 and beyond. This leader owns core infrastructure, enterprise business systems, including clinical and quality platforms, cloud operations, cybersecurity, enterprise architecture, and the technology and governance foundation that enables the company's data, analytics, AI, and automation capabilities. This is a builder role requiring strategic vision, hands-on execution, and the rigor required of a public company in a regulated industry, including GxP, SOX, and SEC cybersecurity expectations.
Essential Duties and Responsibilities:
Required Education and Experience:
Additional Skills, Knowledge, and/or Abilities:
Other Requirements:
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1 pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1 monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally. Avalo is pursuing additional development opportunities in IL-1 driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1 mAb. For more information about Avalo, please visit www.avalotx.com.
ATTENTION: External Agencies and Placement Firms
A member of the Avalo Human Resources Department will contact an agency directly if an open position is eligible to be sourced from an outside recruiting service. Avalo does not accept unsolicited resumes from employment agencies for any employment opportunity. All agencies/recruiters must have a written agreement/SOW in place with Avalo and prior to submitting any resume or CV.
All resumes must be submitted through the appropriate process. Any resumes submitted without an agreement and/or any resumes sent unsolicited through e-mail accounts of Avalo employees will be considered outside of the appropriate process, do not imply or create any obligation on our part, do not impart any restrictions on Avalo with respect to the hiring of any persons whose resumes are so submitted and are not eligible for placement fees.
| Location | Chesterbrook, PA |
Browse dozens of recruiter approved resume templates, layouts and formats. Choose your favorite and make it your own in minutes.
Free resume templatesImprove your existing resume or start from scratch and create a standout, ATS-friendly resume. Add job-specific content, download and apply.
Resume Builder